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Objectives: The aim of this study was to evaluate the cost-effectiveness of 
pertuzumab in combination with trastuzumab and docetaxel as neo-adjuvant 
treatment for locally advanced, inflammatory, or early stage breast cancers that 
overexpress Human Epidermal growth factor Receptor 2 (HER2), from the Italian 
National Health System (SSN) perspective. MethOds: A six state Markov model 
was used to estimate outcomes and costs over a 50-year time horizon. Patients 
were assumed to receive standard neo-adjuvant therapy containing trastuzumab 
and docetaxel or the same regimen plus pertuzumab. Transition probabilities to 
progressive disease and death were based on total pathological complete response 
(pCR) rates observed in the NeoSphere study. A second analysis was carried out 
in which progression-free survival (PFS) was directly modelled on observed 
data. Expected survival was adjusted by utility weights for health states derived 
from literature. Direct medical unit costs were collected from official and pub-
lished Italian sources. Costs and health gains were discounted at an annual 3% 
rate. Probabilistic sensitivity analysis (PSA) was carried out to evaluate uncer-
tainty. Results: Pertuzumab combination was associated with increased QALYs 
and costs relative to standard neo-adjuvant regimen. Acquisition drug cost of 
pertuzumab was the primary contributor to the difference in costs, partially off-
set through the prevention of relapse and worsening. The estimated ICERs range 
between € 3,000 and € 19,000 per QALY. In PSA, pertuzumab combination has very 
high probability of being cost effective relative to standard regimen for a WTP 
threshold of € 40,000 per QALY gained. cOnclusiOns: Breast cancer with HER2 
overexpression is associated with increased tumour aggressiveness, higher rates 
of recurrence and mortality. In the neo-adjuvant setting, pertuzumab in combina-
tion with trastuzumab and docetaxel is expected to be more effective (increased 
probability to reach higher pCR rate and longer PFS) than standard regimen, at a 
favourable cost per QALY gained.
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Objectives: Colorectal cancer is the third most common cancer in Wales, with 2444 
new cases reported in 2012. Incidence increased by 28.5% between 2002 and 2012. 
While survival rates in colorectal cancer are improving globally, the UK continues to 
lag behind other major economies. Recent evidence demonstrates that cetuximab 
can result in significant life extension when added to chemotherapy as a first line 
treatment of RAS wild type metastatic colorectal cancer. At present, cetuximab is 
funded in Wales mainly through Individual Patient Treatment Requests which are 
increasing in number due to the rising demand from both patients and physicians. 
An evidence submission was submitted to AWMSG to highlight this clinical benefit 
and assess the cost effectiveness of cetuximab. MethOds: An economic model 
was developed to assess the cost effectiveness of cetuximab in the management 
of unresectable RAS wt metastatic colorectal cancer in comparison to comparators 
available in the Welsh NHS; FOLFOX, FOLFIRI, or CAPOX alone. This includes a small 
population of patients with metastases confined to the liver who may subsequently 
be eligible for curative resection after treatment with cetuximab plus chemotherapy. 
The time horizon is 10 years and the discount rate applied to both outcomes and 
costs is 3.5%. Cetuximab Welsh Patient Access Scheme (WPAS) price was used in 
all analyses and the dose was set to fortnightly dosing as typically prescribed in 
Wales. Results: Economic analyses estimated an incremental cost effectiveness 
ratio of £29,512 per QALY gained for cetuximab + FOLFOX compared to FOLFOX 
alone and £35,731 per QALY gained for cetuximab + FOLFIRI compared to FOLFIRI 
alone. cOnclusiOns: These analyses demonstrate that cetuximab is a cost effec-
tive treatment and a good use of NHS Wales resources through stratification of 
RAS wild type patients who are likely to respond to treatment and offer patients a 
life-extending treatment option.
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bAckgROund: In September 2014 the European Commission granted market-
ing authorisation for idelalisib with rituximab (I+R) for the treatment of chronic 
lymphocytic leukaemia (CLL) in previously treated patients and treatment-naïve 
patients with a 17p deletion or TP53mutation. Objectives: This study evaluated 
the cost effectiveness of I+R in previously-treated patients according to their eli-
gibility for chemo-immunotherapy in England and Wales. MethOds: A 5-state 
Markov model was constructed from a National Health Service (NHS) perspective 
over a lifetime horizon. Study 116 contained 220 patients for whom chemo-immu-
notherapy was unsuitable owing to poor previous response to such treatment, 
the presence of 17p deletion or TP53mutation, or their fitness, randomised 1:1 
to I+R (intervention) or rituximab with placebo (comparator). Intervention-arm 
data from Study 116 were used to inform the effectiveness of I+R in terms of 
response, time on treatment, progression-free and overall survival. Comparator-
arm data from Study 116 were used to inform the effectiveness of (i) rituximab 
monotherapy, and using further assumptions, (ii) ofatumumab monotherapy and 
Objectives: The objective of this study was to estimate Incremental Cost-
Effectiveness Ratio(ICER) of utilizing eribulin against Treatment of Physician’s 
Choice (TPC) for third line treatment of Metastatic Breast Cancer(MBC) in 
Taiwan. MethOds: Efficacy and safety data was obtained from a multicentre phase 
III clinical trial (EMBRACE) comparing eribulin against TPC. A five-year partitioned 
survival cost-effectiveness analysis(CEA) with a Quality-adjusted Time Without 
Symptoms and Toxicity(Q-TWiST) as the effectiveness measure was developed. 
Costs included in the model were drugs & administration, post-treatment resource 
use, toxicity management and indirect treatment costs. Cost effectiveness was eval-
uated using the Gamma distribution for Overall Survival(OS), Weibull for Progression 
Free Survival(PFS), response duration and, toxicity time. Health state utilities were 
applied to each component and aggregated. In base-case analysis, 3% discount-
ing was applied for both benefits and costs. Deterministic sensitivity analysis was 
used to evaluate sensitivity of the key variables. Results: OS based on Gamma 
extrapolation was 17.26 months in eribulin group versus 14.39 months in TPC group 
for a difference of 2.87 months. Mean time without progressive disease was 4.68 
months for eribulin and 3.96 months for TPC for a difference of 0.72 months. The 
Quality Adjusted Life Years were 0.83 in the eribulin group compared to 0.70 in TPC 
group for a mean incremental improvement of 0.13 years. Treatment costs were 
NTD 351,875 for eribulin and NTD 113,552 for TPC for a difference of NTD 238,323. 
In base-case analysis, the ICER with discounting was NTD 1,823,482. Survival time 
was most sensitive variables on the ICER in this CEA. cOnclusiOns: With an ICER 
of NTD 1,823,482 compared to TPC, eribulin was found to be cost-effective in third 
and later line MBC population in Taiwan. Given the limited number of effective 
therapeutic options available to these patients, eribulin represents a valid option 
for optimizing treatment pathways.
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Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept 
in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer 
(mCRC) in Best Efficacy Subgroup (BES) patients previously treated with oxaliplatino 
compared to FOLFIRI. MethOds: A post-hoc analysis of the VELOUR clinical trial 
revealed an improvement of aflibercept efficacy in a specific subgroup. BES was com-
posed by patients with performance status (PS) 0 with any number of metastatic sites 
or PS 1 with < 2 metastatic sites, exclusive of adjuvant fast relapsers. A Markov model 
with 3 health states (stable disease, progression and death) was used to estimate 
lifetime costs and outcomes (2-weeks cycle duration). Transition from stable disease 
to progression implied the interruption of second-line treatment and administra-
tion of a third-line chemotherapy (72%) or best supportive care (28%). According to 
the National Health System (NHS) perspective only direct costs were considered. 
Cost estimation (€ , 2015) included pharmaceutical and administration cost, adverse 
event management and hospital and medical visits consumption. Ex-factory price 
with mandatory deduction was applied for drug cost estimation. Costs and outcomes 
were 3% annually discounted. Sensitivity analyses (SA) were performed. Results: 
Administration of aflibercept + FOLFIRI as second-line treatment on BES was more 
effective than FOLFIRI, yielding 1.92 LYG (23 life-months gained) compared to 1.55 
LYG (18.6 months). Aflibercept + FOLFIRI accounted a total cost of € 40,449, compared 
to € 25,698 estimated for FOLFIRI. The incremental cost-effectiveness analysis pro-
vided a € 33,373/LYG ratio for aflibercept in combination with FOLFIRI versus FOLFIRI 
for BES. SA results confirmed the model robustness. cOnclusiOns: According to 
a post-hoc analysis, aflibercept in combination with FOLFIRI could increase overall 
survival versus FOLFIRI on BES. Aflibercept + FOLFIRI could be an efficient strategy for 
second-line treatment in specific mCRC patients for the Spanish NHS.
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Objectives: The problem of anthracycline-induced clinical heart failure is an 
important public health concern as it may not be seen for many years and remains 
a life-long threat. We performed a cost-effectiveness analysis of the cardioprotec-
tive effect of Dexrazoxane in advanced/metastatic breast cancer patients treated 
with anthracycline-based chemotherapy in México. MethOds: A decision tree 
model was developed in order to compare dexrazoxane with no treating. The time 
horizon was one year. The main data for dexrazoxane efficacy (surgery require-
ment and functional loss) was obtained from two open label non-comparative 
studies. Main costs taken into account were the drug costs, administration and 
monitoring and surgical costs. Results: Dexrazoxane may lead to important 
savings for the Mexican public health system when it is compared to no treat-
ing. The results derived from the model indicate that Dexrazoxane is associated 
with less cardiac events (39% versus 13%, P < 0.001) and a lower and less severe 
incidence of congestive heart failure (11% versus 1%, P < 0.05) which represent a 
saving of 200,000 USD per patient treated. Tumor response rate was unaffected 
by dexrazoxane therapy. The frequency of adverse events was similar between 
groups and there were no significant between-group differences in the number 
of dose modifications/interruptions. cOnclusiOns: Dexrazoxane is a dominant 
alternative vs no treating since it significantly reduced the occurrence and severity 
of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac 
dysfunction due to previous anthracycline treatment without compromising 
the antitumor efficacy of the chemotherapeutic regimen at a lower cost than no 
treating
